- Home
- REVG vs TLX Comparison
REVG vs TLX Comparison
Compare REVG & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVG
- TLX
- Stock Information
- Founded
- REVG 2008
- TLX 2015
- Country
- REVG United States
- TLX Australia
- Employees
- REVG 5700
- TLX N/A
- Industry
- REVG Auto Manufacturing
- TLX Biotechnology: Pharmaceutical Preparations
- Sector
- REVG Consumer Discretionary
- TLX Health Care
- Exchange
- REVG Nasdaq
- TLX Nasdaq
- Market Cap
- REVG 2.9B
- TLX 3.2B
- IPO Year
- REVG 2017
- TLX N/A
- Fundamental
- Price
- REVG $59.16
- TLX $9.38
- Analyst Decision
- REVG Hold
- TLX Strong Buy
- Analyst Count
- REVG 4
- TLX 3
- Target Price
- REVG $53.00
- TLX $21.33
- AVG Volume (30 Days)
- REVG 1.0M
- TLX 257.4K
- Earning Date
- REVG 09-03-2025
- TLX 01-01-0001
- Dividend Yield
- REVG 0.40%
- TLX N/A
- EPS Growth
- REVG N/A
- TLX N/A
- EPS
- REVG 2.12
- TLX 0.04
- Revenue
- REVG $2,397,000,000.00
- TLX $664,225,558.00
- Revenue This Year
- REVG $3.10
- TLX N/A
- Revenue Next Year
- REVG $7.86
- TLX N/A
- P/E Ratio
- REVG $28.17
- TLX $220.22
- Revenue Growth
- REVG N/A
- TLX 55.35
- 52 Week Low
- REVG $25.76
- TLX $8.93
- 52 Week High
- REVG $64.47
- TLX $30.36
- Technical
- Relative Strength Index (RSI)
- REVG 58.06
- TLX 36.10
- Support Level
- REVG $58.55
- TLX $9.14
- Resistance Level
- REVG $64.47
- TLX $9.53
- Average True Range (ATR)
- REVG 2.47
- TLX 0.24
- MACD
- REVG -0.16
- TLX 0.10
- Stochastic Oscillator
- REVG 59.68
- TLX 25.71
About REVG REV Group Inc.
REV Group Inc is a United States-based designer, manufacturer, and distributor of specialty vehicles and related aftermarket parts and services. During the first fiscal quarter of 2024, the Company formed the Specialty Vehicles Segment by combining the Fire & Emergency and Commercial segment businesses. Additionally, the Recreation segment was renamed Recreational Vehicles. As a result, the Company is now organized into two reportable segments. The company operates in the United States, Canada, and the rest of the world. Maximum of revenue is gained from Specialty Vehicles Segment.
About TLX Telix Pharmaceuticals Limited American Depositary Shares
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.